雷贝拉唑三联治疗幽门螺杆菌相关性消化性溃疡的的疗效观察.docVIP

雷贝拉唑三联治疗幽门螺杆菌相关性消化性溃疡的的疗效观察 　　[摘要] 目的 观察雷贝拉唑联用呋喃唑酮、克拉霉素治疗幽门螺杆菌（Hp）相关性消化性溃疡的疗效。 方法 胃镜检查确认消化性溃疡且13C尿素呼气试验Hp阳性的86例患者，随机分为治疗组（A组）和对照组（B组）各43例；A组口服雷贝拉唑、呋喃唑酮、克拉霉素治疗，B组将A组方案中的雷贝拉唑替换为奥美拉唑。 结果 两组治疗7 d后症状改善率分别为97.67%和88.38%，Hp根治率分别为90.70%和67.44%，两组在症状改善率和Hp根治率上差异有统计学意义（P＜0.05）。 结论 雷贝拉唑三联治疗Hp相关性消化性溃疡在缓解症状、根除Hp较其他方案有更佳的效价比。 　　[关键词] 雷贝拉唑；幽门螺杆菌；消化性溃疡 　　[中图分类号] R573.1 [文献标识码] B [文章编号] 1673-9701（2012）01-075-02 　　 　　Efficacy of rabeprazole based triple therapy in the treatment of helicobacter pylori-related peptic ulcer 　　LI Yangming LUO Zihong 　　Department of Gastroenterology, Dehong Prefecture Border Detachment Hospital in Yunnan Province, Dehong 678400, China 　　 　　[Abstract] Objective To observe the efficacy of rabeprazole, furazolidone and clarithromycin based triple therapy in the treatment of helicobacter pylori-related peptic ulcer. Methods Eighty-six patients with peptic ulcer and Hp infection by endoscopic examination and urea breath test were randomized to treatment group(group A) and control group(group B) with 43 cases in each. Group A took orally rabeprazole, furazolidone and clarithromycin; Group B changed rabeprazole of group A to omeprazole, and others medicine had no change. Results Symptomatic relief was found 97.67% and 88.38% in two groups after 7 days, Hp eradication rate was 90.70% and 67.44%; Symptomatic relief rate and Hp eradication rate of two groups were significantly different(P＜0.05). Conclusion Rabeprazole, furazolidone and clarithromycin based triple therapy in the treatment of helicobacter pylori-related peptic ulcer has good efficacy and low cost. 　　[Key words] Rabeprazole; Helicobacter pylori; Peptic ulcer 　　 　　消化性溃疡是消化内科慢性复发性疾病之一，经临床证实幽门螺杆菌（Helicobacter pylori，Hp）是消化性溃疡发病及复发的重要原因，根除Hp可明显减少溃疡的复发。故在消化性溃疡的治疗上，不论其活动或静止，无论其初发或复发，除了应用抗溃疡药物外，需同时对Hp进行根除[1]。本文对我院2010年7月～2011年5月在本院门诊及住院患者86例的治疗进行分组对照比较，观察雷贝拉唑联用呋喃唑酮和克拉霉素治疗Hp相关性消化性溃疡的疗效。 　　 　　1 资料与方法 　　1.1 病例选择 　　本组资料共86例，A组43例，男36例，女7例，年龄28～71岁，平均49.5岁；其中胃溃疡（GU）16例，十二指肠溃疡（DU）22例，复合溃疡5例，Hp检查（+